Takeaway

• In patients with metastatic/unresectable melanoma not responding to anti-PD-1 therapy, the combination of ipilimumab/nivolumab led to improvements in progression-free survival (PFS) and objective response rate (ORR) compared to ipilimumab alone.
• The toxicity was manageable.
• Ipilimumab/nivolumab is an appropriate next-line treatment in this population.

Why this matters

• The appropriate sequence...